Cidara Therapeutics Inc (CDTX)
20.40
+2.95
(+16.91%)
USD |
NASDAQ |
Nov 22, 16:00
21.31
+0.91
(+4.46%)
After-Hours: 20:00
Cidara Therapeutics Revenue (TTM)
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 61.36M |
| March 31, 2024 | 66.15M |
| December 31, 2023 | 83.79M |
| September 30, 2023 | 50.79M |
| June 30, 2023 | 82.32M |
| March 31, 2023 | 83.45M |
| December 31, 2022 | 64.45M |
| September 30, 2022 | 61.29M |
| June 30, 2022 | 27.63M |
| Date | Value |
|---|---|
| March 31, 2022 | 54.27M |
| December 31, 2021 | 49.57M |
| September 30, 2021 | 46.08M |
| June 30, 2021 | 41.42M |
| March 31, 2021 | 11.94M |
| December 31, 2020 | 12.07M |
| September 30, 2020 | 10.15M |
| June 30, 2020 | 26.84M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
10.15M
Minimum
Sep 2020
83.79M
Maximum
Dec 2023
49.03M
Average
50.79M
Median
Sep 2023
Revenue (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 2.753B |
| Arbutus Biopharma Corp | 6.742M |
| GlycoMimetics Inc | -- |
| FibroGen Inc | 180.01M |
| Cue Biopharma Inc | 9.532M |